PEDIATRIX MEDICAL GROUP INC (MD) Fundamental Analysis & Valuation

NYSE:MD • US58502B1061

19.75 USD
+0.46 (+2.38%)
At close: Mar 6, 2026
19.88 USD
+0.13 (+0.66%)
After Hours: 3/6/2026, 8:04:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This MD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to MD. MD was compared to 101 industry peers in the Health Care Providers & Services industry. MD scores excellent on profitability, but there are some minor concerns on its financial health. MD is valued quite cheap, while showing a decent growth score. This is a good combination! With these ratings, MD could be worth investigating further for value investing!.


Dividend Valuation Growth Profitability Health

7

1. MD Profitability Analysis

1.1 Basic Checks

  • In the past year MD was profitable.
  • MD had a positive operating cash flow in the past year.
  • In multiple years MD reported negative net income over the last 5 years.
  • Each year in the past 5 years MD had a positive operating cash flow.
MD Yearly Net Income VS EBIT VS OCF VS FCFMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M -500M -1B

1.2 Ratios

  • MD's Return On Assets of 7.36% is amongst the best of the industry. MD outperforms 88.12% of its industry peers.
  • Looking at the Return On Equity, with a value of 19.10%, MD belongs to the top of the industry, outperforming 87.13% of the companies in the same industry.
  • MD has a Return On Invested Capital of 9.88%. This is in the better half of the industry: MD outperforms 79.21% of its industry peers.
  • MD had an Average Return On Invested Capital over the past 3 years of 8.21%. This is in line with the industry average of 9.07%.
  • The 3 year average ROIC (8.21%) for MD is below the current ROIC(9.88%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 7.36%
ROE 19.1%
ROIC 9.88%
ROA(3y)0.01%
ROA(5y)1.53%
ROE(3y)-0.32%
ROE(5y)4.22%
ROIC(3y)8.21%
ROIC(5y)7.97%
MD Yearly ROA, ROE, ROICMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20 -40 -60 -80 -100

1.3 Margins

  • With an excellent Profit Margin value of 8.64%, MD belongs to the best of the industry, outperforming 91.09% of the companies in the same industry.
  • MD's Profit Margin has improved in the last couple of years.
  • MD's Operating Margin of 12.07% is amongst the best of the industry. MD outperforms 84.16% of its industry peers.
  • MD's Operating Margin has improved in the last couple of years.
Industry RankSector Rank
OM 12.07%
PM (TTM) 8.64%
GM N/A
OM growth 3Y5.99%
OM growth 5Y4.02%
PM growth 3Y36.96%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MD Yearly Profit, Operating, Gross MarginsMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20 -40 -60 -80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. MD Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so MD is still creating some value.
  • Compared to 1 year ago, MD has less shares outstanding
  • The number of shares outstanding for MD has been reduced compared to 5 years ago.
  • The debt/assets ratio for MD has been reduced compared to a year ago.
MD Yearly Shares OutstandingMD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
MD Yearly Total Debt VS Total AssetsMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B 5B

2.2 Solvency

  • MD has an Altman-Z score of 2.02. This is not the best score and indicates that MD is in the grey zone with still only limited risk for bankruptcy at the moment.
  • MD has a Altman-Z score (2.02) which is in line with its industry peers.
  • MD has a debt to FCF ratio of 2.36. This is a good value and a sign of high solvency as MD would need 2.36 years to pay back of all of its debts.
  • The Debt to FCF ratio of MD (2.36) is better than 77.23% of its industry peers.
  • MD has a Debt/Equity ratio of 0.66. This is a neutral value indicating MD is somewhat dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.66, MD is in line with its industry, outperforming 55.45% of the companies in the same industry.
  • Although MD's pure debt/equity ratio does not look good, it has limited outstanding debt compared to the Free Cash Flow. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
Industry RankSector Rank
Debt/Equity 0.66
Debt/FCF 2.36
Altman-Z 2.02
ROIC/WACC1.22
WACC8.1%
MD Yearly LT Debt VS Equity VS FCFMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

2.3 Liquidity

  • A Current Ratio of 1.66 indicates that MD should not have too much problems paying its short term obligations.
  • The Current ratio of MD (1.66) is better than 66.34% of its industry peers.
  • MD has a Quick Ratio of 1.66. This is a normal value and indicates that MD is financially healthy and should not expect problems in meeting its short term obligations.
  • With a decent Quick ratio value of 1.66, MD is doing good in the industry, outperforming 68.32% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.66
Quick Ratio 1.66
MD Yearly Current Assets VS Current LiabilitesMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. MD Growth Analysis

3.1 Past

  • MD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 36.24%, which is quite impressive.
  • The Earnings Per Share has been growing by 10.01% on average over the past years. This is quite good.
  • The Revenue has decreased by -4.92% in the past year.
  • Measured over the past years, MD shows a small growth in Revenue. The Revenue has been growing by 1.99% on average per year.
EPS 1Y (TTM)36.24%
EPS 3Y6.72%
EPS 5Y10.01%
EPS Q2Q%-1.96%
Revenue 1Y (TTM)-4.92%
Revenue growth 3Y-0.99%
Revenue growth 5Y1.99%
Sales Q2Q%-1.71%

3.2 Future

  • MD is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 1.48% yearly.
  • MD is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.60% yearly.
EPS Next Y10.99%
EPS Next 2Y8.08%
EPS Next 3Y2.62%
EPS Next 5Y1.48%
Revenue Next Year2.7%
Revenue Next 2Y2.49%
Revenue Next 3Y4.56%
Revenue Next 5Y4.6%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
MD Yearly Revenue VS EstimatesMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 1B 2B 3B
MD Yearly EPS VS EstimatesMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 1 2 3 4

More info and screens

Find the best growth stocksShow best growing peers

8

4. MD Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 9.73, the valuation of MD can be described as very reasonable.
  • 92.08% of the companies in the same industry are more expensive than MD, based on the Price/Earnings ratio.
  • MD is valuated cheaply when we compare the Price/Earnings ratio to 26.29, which is the current average of the S&P500 Index.
  • A Price/Forward Earnings ratio of 8.77 indicates a reasonable valuation of MD.
  • Based on the Price/Forward Earnings ratio, MD is valued cheaper than 93.07% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 24.57, MD is valued rather cheaply.
Industry RankSector Rank
PE 9.73
Fwd PE 8.77
MD Price Earnings VS Forward Price EarningsMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

  • MD's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. MD is cheaper than 88.12% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, MD is valued cheaply inside the industry as 92.08% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 6.71
EV/EBITDA 6.44
MD Per share dataMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • MD has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)0.89
PEG (5Y)0.97
EPS Next 2Y8.08%
EPS Next 3Y2.62%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MD Dividend Analysis

5.1 Amount

  • No dividends for MD!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MD Fundamentals: All Metrics, Ratios and Statistics

PEDIATRIX MEDICAL GROUP INC

NYSE:MD (3/6/2026, 8:04:00 PM)

After market: 19.88 +0.13 (+0.66%)

19.75

+0.46 (+2.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)02-19
Earnings (Next)05-04
Inst Owners98.9%
Inst Owner Change1.26%
Ins Owners1.87%
Ins Owner Change-1.02%
Market Cap1.70B
Revenue(TTM)1.91B
Net Income(TTM)165.39M
Analysts78.67
Price Target21.93 (11.04%)
Short Float %3.53%
Short Ratio3.82
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)14.87%
Min EPS beat(2)-9.94%
Max EPS beat(2)39.68%
EPS beat(4)3
Avg EPS beat(4)20.9%
Min EPS beat(4)-9.94%
Max EPS beat(4)39.68%
EPS beat(8)7
Avg EPS beat(8)17.99%
EPS beat(12)7
Avg EPS beat(12)8.59%
EPS beat(16)8
Avg EPS beat(16)5.12%
Revenue beat(2)1
Avg Revenue beat(2)-0.49%
Min Revenue beat(2)-1.41%
Max Revenue beat(2)0.42%
Revenue beat(4)1
Avg Revenue beat(4)-1.1%
Min Revenue beat(4)-1.97%
Max Revenue beat(4)0.42%
Revenue beat(8)2
Avg Revenue beat(8)-1.43%
Revenue beat(12)2
Avg Revenue beat(12)-2.28%
Revenue beat(16)2
Avg Revenue beat(16)-2.52%
PT rev (1m)-5.15%
PT rev (3m)-5.15%
EPS NQ rev (1m)-0.55%
EPS NQ rev (3m)-0.55%
EPS NY rev (1m)0%
EPS NY rev (3m)19.44%
Revenue NQ rev (1m)-1.44%
Revenue NQ rev (3m)-1.44%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.1%
Valuation
Industry RankSector Rank
PE 9.73
Fwd PE 8.77
P/S 0.89
P/FCF 6.71
P/OCF 6.26
P/B 1.96
P/tB N/A
EV/EBITDA 6.44
EPS(TTM)2.03
EY10.28%
EPS(NY)2.25
Fwd EY11.41%
FCF(TTM)2.94
FCFY14.89%
OCF(TTM)3.16
OCFY15.98%
SpS22.29
BVpS10.08
TBVpS-4.79
PEG (NY)0.89
PEG (5Y)0.97
Graham Number21.46
Profitability
Industry RankSector Rank
ROA 7.36%
ROE 19.1%
ROCE 12.93%
ROIC 9.88%
ROICexc 13.71%
ROICexgc 1686.9%
OM 12.07%
PM (TTM) 8.64%
GM N/A
FCFM 13.2%
ROA(3y)0.01%
ROA(5y)1.53%
ROE(3y)-0.32%
ROE(5y)4.22%
ROIC(3y)8.21%
ROIC(5y)7.97%
ROICexc(3y)10.42%
ROICexc(5y)9.77%
ROICexgc(3y)618.91%
ROICexgc(5y)394.62%
ROCE(3y)10.75%
ROCE(5y)10.43%
ROICexgc growth 3Y208.98%
ROICexgc growth 5Y85.34%
ROICexc growth 3Y17.7%
ROICexc growth 5Y11.82%
OM growth 3Y5.99%
OM growth 5Y4.02%
PM growth 3Y36.96%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.85
Health
Industry RankSector Rank
Debt/Equity 0.66
Debt/FCF 2.36
Debt/EBITDA 2.26
Cap/Depr 84.57%
Cap/Sales 0.96%
Interest Coverage 6.72
Cash Conversion 107.19%
Profit Quality 152.75%
Current Ratio 1.66
Quick Ratio 1.66
Altman-Z 2.02
F-Score8
WACC8.1%
ROIC/WACC1.22
Cap/Depr(3y)81.68%
Cap/Depr(5y)85.74%
Cap/Sales(3y)1.24%
Cap/Sales(5y)1.38%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.24%
EPS 3Y6.72%
EPS 5Y10.01%
EPS Q2Q%-1.96%
EPS Next Y10.99%
EPS Next 2Y8.08%
EPS Next 3Y2.62%
EPS Next 5Y1.48%
Revenue 1Y (TTM)-4.92%
Revenue growth 3Y-0.99%
Revenue growth 5Y1.99%
Sales Q2Q%-1.71%
Revenue Next Year2.7%
Revenue Next 2Y2.49%
Revenue Next 3Y4.56%
Revenue Next 5Y4.6%
EBIT growth 1Y25.81%
EBIT growth 3Y4.93%
EBIT growth 5Y6.1%
EBIT Next Year16.32%
EBIT Next 3Y7%
EBIT Next 5YN/A
FCF growth 1Y36.89%
FCF growth 3Y22.56%
FCF growth 5Y7.52%
OCF growth 1Y31.23%
OCF growth 3Y17.54%
OCF growth 5Y5.79%

PEDIATRIX MEDICAL GROUP INC / MD FAQ

What is the ChartMill fundamental rating of PEDIATRIX MEDICAL GROUP INC (MD) stock?

ChartMill assigns a fundamental rating of 6 / 10 to MD.


What is the valuation status for MD stock?

ChartMill assigns a valuation rating of 8 / 10 to PEDIATRIX MEDICAL GROUP INC (MD). This can be considered as Undervalued.


How profitable is PEDIATRIX MEDICAL GROUP INC (MD) stock?

PEDIATRIX MEDICAL GROUP INC (MD) has a profitability rating of 7 / 10.


What are the PE and PB ratios of PEDIATRIX MEDICAL GROUP INC (MD) stock?

The Price/Earnings (PE) ratio for PEDIATRIX MEDICAL GROUP INC (MD) is 9.73 and the Price/Book (PB) ratio is 1.96.